U

UCB Pharma

Biopharmaceuticals for neurology and immunology therapies

VIE Business Excellence Data Analyst

Full-TimePosted on 10/19/2026
No salary listed
Entry
Master's
Braine-l'Alleud, Belgium
In Person
Data & AnalyticsBusiness Intelligence

About the job

Requirements
  • A Master's degree or equivalent in Data Science, Business Analytics, Engineering, Management Information Systems, Industrial Engineering, Continuous Improvement, or a related field.
  • Initial academic or professional experience in data analysis, Business Intelligence, or process improvement.
  • Very good command of Excel and PowerPoint.
  • Ability to structure data, produce reliable analyses, and translate results into clear recommendations.
  • Fluent English.
  • Meet the VIE assignment prerequisites: be 18 to 28 years old; hold the nationality of a European Economic Area member country; have not worked or lived in the country where the mission takes place; be available for the full-time mission; if French or dual French nationality, comply with French national service obligations; and have a clean criminal record.
Responsibilities
  • Structure, consolidate, and analyze performance data from various sources.
  • Develop and maintain dashboards and indicators to improve visibility, decision-making, and priority tracking.
  • Contribute to harmonizing and digitalizing Business Excellence processes, particularly performance, risk, quality, and partner engagement.
  • Participate in identifying use cases for data analytics, automation, and artificial intelligence, and support their prototyping and deployment.
  • Collaborate with process owners, External Manufacturing, Quality, Supply, IT/Data teams, and other internal stakeholders.
  • Document developed solutions and contribute to their adoption by users.
Desired Qualifications
  • Experience with Power BI is highly desirable.
  • Knowledge of Python, SQL, automation, or artificial intelligence is an asset.
  • French is an asset.

About the company

U

UCB Pharma

View
Website

UCB Pharma focuses on developing treatments for severe diseases in neurology and immunology. It discovers, develops, and commercializes novel molecules and generates products aimed at improving patient lives. The company works by researching and developing therapies, integrating patient insights to guide innovation, and investing over a quarter of revenue into scientific research. Its global presence (about 9,000 employees across 40 countries) and €5.3 billion 2023 revenue reflect its scale and commitment to bringing therapies to patients worldwide. UCB differentiates itself by combining direct patient engagement with substantial R&D investment to address unmet needs in neurology and immunology, aiming to transform lives through science and patient care.

Company Size

10,001+

Company Stage

IPO

Headquarters

City of Brussels, Belgium

Founded

1928

Get referred to UCB Pharma

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • H1 2026 revenue rose 22% to €4.27 billion, with EBITDA margin reaching 40.7%.
  • UCB raised 2026 guidance on July 30, 2026, and lifted Bimzelx peak sales to €7 billion.
  • Georgia’s $2 billion biologics campus, announced March 24, 2026, strengthens U.S. supply and jobs.

What critics are saying

  • Bimzelx concentration intensifies if rivals Cosentyx, Skyrizi, and Icotrokinra erode 2027 growth.
  • August 31, 2026 U.S. pricing concessions and GENEROUS participation compress future launch economics.
  • Nayzilam faces recurring generic pressure; Cipla and Hikma litigation signals durable patent erosion risk.

What makes UCB Pharma unique

  • Bimzelx’s dual IL-17A/F mechanism drove BE BOLD superiority on March 11, 2026.
  • UCB won ATG-201 worldwide rights on March 3, 2026, expanding next-generation immunology.
  • UCB integrates patient-led digital care through DCTx programs, accelerating diagnosis and treatment pathways.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Flexible Work Hours
  • Hybrid Work Options
  • Remote Work Options
  • Paid Vacation
  • PTO/vacation
  • Paid Sick Leave
  • Paid Holidays
  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match

Growth & Insights and Company News

Headcount

6 month growth

7%

1 year growth

7%

2 year growth

7%
MarketScreener
Oct 16th, 2026
FDA green light for UCB and positive view from DB.

FDA green light for UCB and positive view from DB. Belgian biopharmaceutical group UCB has announced that the US FDA has approved a new administration option for Zilbrysq (zilucoplan), its treatment for generalized myasthenia gravis in adult patients with anti-acetylcholine receptor (AChR) antibodies. Published on 10/16/2026 at 04:00 am EDT MarketScreener.com The authorization covers an auto-injector enabling daily subcutaneous administration by the patient. It is the first device of its kind approved in the United States for this indication. Until now, Zilbrysq had been available as a prefilled syringe. The approval is notably based on a phase 1 study demonstrating the bioequivalence of the two administration methods and on a phase 3b study involving 31 patients. The latter showed that 99.8% of administrations using the auto-injector delivered a full dose of the treatment. Another study, conducted among 100 participants, found that 90% had successfully completed their first injection without prior training. UCB expects to commercialize the new auto-injector in Q1 2027. Meanwhile, Deutsche Bank commented on two third-party surveys covering physicians' reception of the phase 2 data for Tulisokibart in hidradenitis suppurativa (HS) and the latest update on Icotyde in light of the solid launch currently underway at Johnson & Johnson. These two factors are viewed as slight negatives for UCB, although the first is fully consistent with the conclusions most investors drew from the recent conference, while the second reinforces the reasons why investors are apprehensive about the upcoming results for oral Remibrutinib in HS. Nevertheless, Deutsche Bank believes this is more than fully priced in the stock's current valuation; it therefore continues to view the stock as a buy opportunity. The broker therefore has a buy rating on the stock, with a target price of €295. (C) MarketScreener.com - 2026

LQ Ventures
Oct 9th, 2026
Key dermatology treatment trends to watch at EADV 2026.

Key dermatology treatment trends to watch at EADV 2026. Atopic dermatitis: IL-13, IL-18, JAK inhibitors and emerging therapies. IL-13, IL-18, IL-4Rα, JAK and regulatory T-cell approaches will compete on durability, difficult-to-treat sites, dosing and treatment simplicity. Hidradenitis suppurativa: tulisokibart, lutikizumab and abdakibart. Tulisokibart, lutikizumab and abdakibart will test whether targeting inflammatory and fibrotic biology translates into meaningful differentiation in tunnels, scarring and deeper disease. Alopecia areata: bempikibart, ritlecitinib and baricitinib. Bempikibart, ritlecitinib and baricitinib data will shift attention toward long-term disease control, treatment-free response and adolescent treatment. Psoriasis: icotrokinra, zasocitinib and oral treatment competition. Two-year icotrokinra data and zasocitinib versus deucravacitinib could raise expectations for oral psoriasis therapies beyond convenience alone. Competitor and industry signals at EADV 2026. Pfizer, Johnson & Johnson, Novartis, AbbVie, Lilly and UCB: dermatology competition. Pfizer, Johnson & Johnson, Novartis, AbbVie, Lilly, UCB and other companies are emphasizing earlier intervention, sustained disease control and more individualized systemic treatment strategies. Emerging dermatology pipeline: new mechanisms and clinical data. Oturkibart, zumilokibart/APG777, bempikibart, daxdilimab, lunsekimig, tulisokibart and MG-K10 add new mechanisms and late-breaking datasets to watch. Artificial intelligence and machine learning at EADV 2026. AI in dermatology: diagnosis, melanoma risk prediction and dermoscopy. Sessions will focus on AI-supported diagnosis, melanoma risk prediction, dermoscopy, teledermatology and image-based assessment rather than drug discovery. Clinical integration: MELAPRED, Vision transformers and 3D imaging. MELAPRED, Vision Transformer dermoscopy and 3D total-body photography will test whether AI can add value alongside dermatologist assessment. What LucidQuest Ventures LTD is watching after EADV 2026. * Whether emerging hidradenitis suppurativa mechanisms translate into clinically meaningful differentiation. * Whether oral psoriasis therapies deliver deeper, durable disease control at high-impact sites. * Whether longer-term clinical datasets establish treatment durability as a stronger competitive differentiator. * Whether AI evidence is strong enough to support routine dermatology diagnosis, risk assessment and monitoring. Download the EADV 2026 preview report. Download LucidQuest's EADV 2026 preview report for deeper analysis of emerging dermatology treatments, clinical developments and competitive signals. Build your schedule around the sessions that matter most. Contact LucidQuest Ventures LTD for end-to-end conference coverage.

Georgia Public Broadcasting
Oct 9th, 2026
GPB evening headlines for October 9, 2026.

GPB evening headlines for October 9, 2026. October 9, 2026 3:54 PM Authorities are urging Georgians to prepare as Hurricane Isaias is expected to bring heavy rain and damaging winds. Democratic U.S. Sen. Jon Ossoff and his Republican challenger Mike Collins faced off in a live televised debate. Belgian pharmaceutical maker UCB broke ground today on a $2 billion drug manufacturing plant in Gwinnett County. Support local journalism. GPB believes that everyone should have access to trustworthy, fact-based stories that connect them to their community and outward to the wider world. Your donation will help Georgia Public Broadcasting in its efforts to unite and uplift Georgia. GPB is vital. Always educational, essential, inspiring and grounding. So happy to be a supporter. - Kelli D., Athens, Ga. The latest from GPB News Support quality journalism. GPB is committed to bringing you comprehensive news coverage from Georgia, across the country and around the world. Your support makes this possible. Please consider making a gift today to support this vital public service.

PR Newswire
Aug 31st, 2026
UCB strikes deal with US government to lower medicine costs, invest $5B in Georgia manufacturing

UCB, a Belgian biopharmaceutical company, has reached an agreement with the US government to lower medicine costs and boost American manufacturing. The deal includes a balanced pricing approach for future drug launches and participation in the government's GENEROUS programme. Under the agreement, UCB will avoid Section 232 pharmaceutical tariffs and future pricing mandates. The company is expanding its US manufacturing footprint with a new biologics facility in Georgia, representing its largest manufacturing investment. The facility is expected to generate $5 billion in economic impact and create over 330 highly skilled jobs. UCB will also donate Keppra, an FDA-recognised essential epilepsy medicine, to the national stockpile. The company currently employs nearly 2,000 people in the US, a 70% increase since 2017, with over 25% dedicated to research and development.

Antengene
Aug 25th, 2026
Antengene receives Clinical Trial approval in Australia for Phase I ATTRACT study of ATG-201 (CD19 x CD3 TCE) in B cell-related autoimmune diseases.

Antengene receives Clinical Trial approval in Australia for Phase I ATTRACT study of ATG-201 (CD19 x CD3 TCE) in B cell-related autoimmune diseases. Release date: 2026-08-25 Shanghai and Hong Kong, PRC, August 25, 2026 - Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies, today announced that the Phase I ATTRACT study of its proprietary ATG-201, a CD19/CD3 bispecific T-cell engager antibody for B cell-related autoimmune diseases, has received approval from the Human Research Ethics Committee (HREC) in Australia, and completed the Clinical Trial Notification (CTN) process with the Therapeutic Goods Administration (TGA). ATG-201 is a CD19 targeting bispecific TCE incorporating steric hindrance masking technology, designed to eliminate CD19-expressing B cells. This bispecific interaction with T and B cells through CD3 and CD19 has demonstrated potential in treating B cell-driven diseases by leveraging the body's own immune system for precise and potent action. This is a Phase I clinical study designed to evaluate the safety, tolerability and preliminary efficacy of ATG-201 monotherapy in adult patients with B cell related autoimmune diseases. The study will consist of two phases: dose escalation and dose expansion. The primary objectives of the study are to evaluate the safety and tolerability of ATG-201 monotherapy and to determine its recommended Phase II dose (RP2D). Secondary objectives include evaluating the pharmacokinetic (PK) and pharmacodynamic (PD) profiles, immunogenicity, preliminary efficacy of ATG-201. Antengene and UCB have entered into an agreement that grants UCB worldwide exclusive rights to further develop, manufacture, and commercialize ATG-201, and access to its associated manufacturing technology in relation to ATG-201. Antengene will conduct the phase I clinical trials in China and Australia. The clinical trial approval in Australia, following the clearance of ATG-201's clinical trial application by China's NMPA in June this year, marks an important advancement in Antengene's multi-regional development strategy for ATG-201. Together, these milestones demonstrate Antengene's ability to execute efficiently across key clinical markets and reflect the company's forward-looking approach to building ATG-201 into a potential global program for B cell-related autoimmune diseases. As Antengene continues to expand its innovation focus beyond oncology and hematology into autoimmune diseases, the company remains committed to addressing areas of significant unmet medical need and to developing differentiated, potentially first-in-class and/or best-in-class therapies for patients worldwide. About Antengene Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical to commercial stages, with key investigational candidates including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), ATG-125 (B7-H3 x PD-L1 bispecific ADC), ATG-207 (αCD3-TGF-β bifunctional fusion protein), as well as T cell engager (TCE) programs developed using Antengene's proprietary AnTenGager(R) platform. AnTenGager(R), is Antengene's proprietary TCE 2.0 platform, featuring "2+1" bivalent binding for low expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform's broad applicability across autoimmune disease, solid tumors and hematological malignancies, with programs targeting CD19 x CD3 (ATG-201 for B cell-related autoimmune diseases; partnered with UCB), CDH6 x CD3 (ATG-106 for ovarian cancer and kidney cancer; partnered with K2 Therapeutics established by MPM BioImpact), ALPPL2 x CD3 (ATG-112 for gynecological tumors, digestive system malignancies, bladder cancer and NSCLC), LY6G6D x CD3 (ATG-110 for microsatellite-stable colorectal cancer), GPRC5D x CD3 (ATG-021 for multiple myeloma), LILRB4 x CD3 (ATG-102 for acute myeloid leukemia and chronic myelomonocytic leukemia) and FLT3 x CD3 (ATG-107 for acute myeloid leukemia). To date, Antengene has obtained 34 investigational new drug (IND) approvals in the U.S. and Asia, and obtained new drug application (NDA) approvals in 10 Asia Pacific markets. Its lead commercial asset, XPOVIO(R)(selinexor), is approved in the Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia, and has been included in the national insurance schemes in five of these markets (Mainland of China, Taiwan China, Australia, South Korea and Singapore). Forward-looking statements The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, Antengene undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that its actual future results or performance may be materially different from what Antengene expect. In this article, statements of, or references to, its intentions or those of any of its Directors or its Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2025, and the documents subsequently submitted to the Hong Kong Stock Exchange.